Introduction: Initial, landmark studies on n-3 polyunsaturated fatty acids (n-3 PUFAs) confirmed their beneficial effects in the prevention of the cardiovascular diseases, especially in patients with coronary artery disease (CAD). However due to significant progress in treatment of cardiovascular diseases and assessment of n-3 PUFA in variety of doses recent studies have been inconclusive. Objectives: Assess the effect of n-3 PUFA treatment at a dose of 2 g per day on endothelial function, selected coagulation parameters and platelet function in patients in patients with documented chronic coronary syndrome (CCS) and type 2 diabetes (T2D). Additionally, to assess the effect of the fatty acid composition of the serum phospholipid fraction on the clinical course of CAD. Methods: To assess the effect of n-3 PUFA on selected cardiovascular parameters patients were randomized in 1:1 ratio into two groups: 1) optimal medical therapy (OMT) and n-3 PUFA at the dose of 2 g per day— n-3 PUFA group; or 2) placebo and OMT — placebo group; and then treated for 3 months. The evaluation of the fatty acid composition of serum phospholipids was a case-control comparison of patients with acute phase myocardial infarction (AMI) vs. CCS (as a control group). The fatty acid composition of the serum phospholipid was determined by gas chromatography. Results: Despite significant increase in given ; n-3 PUFAs — no significant changes in endothelial function , thrombin generation, fibrin clot properties and platelet function were observed. In the assessment of the fatty acid composition of the serum phospholipid in patients in the AMI vs. CCS, it was found that in both groups saturated fatty acids and n-6 polyunsaturated fatty acids were respectively the largest fraction of fatty acids. Importantly, the multivariate analysis showed that among assessed fatty acids — palmitoleic and eicosadienoic acids were independent predictors of myocardial infarction. Conclusions: Treatment with 2 g of n-3 PUFA daily did not improve endothelium function, selected coagulation parameters and platelet activation. The fatty acid composition of serum phospholipids in patients in the AMI differs significantly when compared to patients with the chronic coronary syndrome.
26 cze 2023
18 maj 2022
11
13
http://dl.cm-uj.krakow.pl:8080/publication/4661
Nazwa wydania | Data |
---|---|
ZB-132359 | 26 cze 2023 |
Siniarski, Aleksander
Mostowik, Magdalena
Drobniak-Hełdak, Dominika
Cyganek, Katarzyna
Sroka-Oleksiak, Agnieszka
Podolec, Jakub.
Podolec, Jakub
Kosiniak-Kamysz, Władysław